When you’ve got Tony Robbins, Dr. Peter Diamandis, and Dr. William Kapp walking into the same room, it’s either the setup to a very expensive punchline or the beginning of a company that doesn’t just add years to life, but life to years. Fountain Life just secured $18M in fresh Series B capital to make sure it’s the latter.
Led by EOS Ventures, with backing from board heavyweights like Todd Wanek and Dr. B.K. Modi, this raise pushes Fountain Life’s total funding to $108M. That’s not pocket change, it’s confidence capital from folks who bet on outcomes, not optimism. And the outcome here? Diagnosing asymptomatic, life threatening conditions in 14% of its earliest members. That’s not disruption. That’s prevention playing offense with tech that doesn’t miss.
Founded in 2020 out of a merger between Dr. William Kapp’s Longevity Performance Center and the vision of Tony Robbins and Dr. Peter Diamandis, Fountain Life isn’t selling wellness fairy dust. They’re tracking over 100 biomarkers using AI, advanced diagnostics, and full-body scans. This isn’t yoga class with a blood panel, it’s medical-grade foresight for those who don’t wait for bad news to show up uninvited. Their Zori AI platform is trained on 1,000+ functional medicine texts and makes ChatGPT look like it skipped biology.
They’re currently operating out of Naples, Orlando, Dallas, and Westchester, with Houston coming online in December and Miami and LA locked for Q2 2026. Memberships start at $10K/year and top out at $30K. That may sound steep, but when asymptomatic kidney cancer or a brain aneurysm gets spotted before it’s an obituary, $30K suddenly looks like a rounding error.
Let’s not forget: this is the same Fountain Life that quietly scooped up LifeOmic in 2023, folded in cloud storage, EHR capabilities, and a biometric symphony of AI/ML integrations, and made it look easy. Under the leadership of Dr. William Kapp as CEO, Chris Hemp as CTO, and President Shawn Buchheit running operations, this isn’t a med spa dressed in tech drag. This is healthcare engineered for people who’d rather live optimized than die surprised.
With regenerative therapies under FDA trials, Zori AI at the clinical front, and a pipeline of new centers ready to drop like exclusive sneaker releases, Fountain Life isn’t just scaling, they’re shaping a future where premium preventative care is the standard, not the splurge.
This round doesn’t just fund growth. It fuels a movement. And if you’re still waiting for traditional healthcare to catch up? Don’t hold your breath. Fountain Life’s already two steps ahead, scanning, testing, and leveling up longevity, one biomarker at a time.
